You are viewing the site in preview mode

Skip to main content

Advertisement

Table 2 Baseline characteristics and clinical outcomes of patients with P. mirabilis bacteremia

From: The impact of production of extended-spectrum β-lactamases on the 28-day mortality rate of patients with Proteus mirabilis bacteremia in Korea

Factors non-ESBL-producing group N = 48 ESBL producing group N = 14 p value
Age, y, median(IQR) 71.0 (60.5–79) 74.5 (61.0–80.25) 0.706
 Age ≥ 65 years, n(%) 30 (60.0) 9 (64.3) 0.903
Male, n(%) 18 (37.5) 9 (64.3) 0.075
BMI, kg/m2,median(IQR) 22.37 (20.51–25.54) 21.21 (18.80–23.46) 0.247
Infection source
 Urinary tract infection, n(%) 28 (58.3) 4 (28.6) 0.05
 Pneumonia, n(%) 3 (6.3) 6 (42.9) 0.003
 Skin and soft tissue infection, n(%) 1 (2.1) 1 (7.1) 0.403
 Biliary infection, n(%) 9 (18.8) 0 (0) 0.105
 Catheter related infection, n(%) 2 (4.2) 1 (7.1) 0.543
 Others, n(%) 5 (10.5) 2 (14.3) 0.61
Comorbidities
 HTN, n(%) 31 (64.6) 7 (50) 0.324
 DM, n(%) 19 (39.6) 5 (35.7) 0.794
 Cardiovascular disease, n(%) 4 (8.3) 4 (28.6) 0.069
 Chronic kidney disease, n(%) 6 (12.5) 1 (7.1) 1.000
 Chronic liver disease, n(%) 3 (6.3) 3 (21.4) 0.122
 Solid tumor, n(%) 25 (52.1) 7 (50) 0.891
 Hematologic malignancy, n(%) 2 (4.2) 0 (0) 1.000
 Solid organ transplantation, n(%) 3 (6.3) 0 (0) 1.000
 Charlson score, median(IQR) 2.0 (1.0–2.75) 2.0 (1.0–3.25) 0.151
Predisposing factors
 Neutropenia, n(%) 2 (4.2) 0 (0) 1.000
 Chemotherapy, n(%) 5 (10.4) 3 (21.4) 0.365
 Nursing home residence, n(%) 7 (14.6) 0 (0) 0.334
 Hemodialysis, n(%) 7 (14.6) 4 (28.6) 0.249
 ICU care, n(%) 11 (22.9) 8 (57.1) 0.022
 Maintaining foley catheter, n(%) 11 (22.9) 6 (42.9) 0.141
 Maintaining PEG tube, n(%) 1 (2.1) 4 (28.6) 0.008
 Previous antibiotic use 13 (27.1) 7 (50) 0.12
  Cephalosporins, n(%) 6 (12.5) 2 (14.3) 1.000
  Carbapenems, n(%) 2 (4.2) 2 (4.2) 0.217
  Fluorquinolones, n(%) 2 (4.2) 1 (7.1) 0.543
  BLBLIs, n(%) 4 (8.4) 1 (7.1) 1.000
Clinical presentation
 Shock, n(%) 17 (35.4) 6 (42.9) 0.612
 Acute kidney injury, n(%) 15 (31.3) 2 (14.3) 0.313
 APACHE II score, median(IQR) 12.0 (8.0–16.75) 13.5 (10.75–19.25) 0.115
 SOFA score, median(IQR) 3.0 (1.0–5.75) 4.0 (1.0–6.5) 0.85
Outcomes
 Inappropriate antimicrobial therapy, n(%) 9 (18.8) 6 (42.9) 0.082
 Overall mortality, n(%) 25 (52.1) 11 (78.6) 0.077
 28-day mortality, n(%) 4 (8.3) 7 (50) 0.001
  1. ESBL extended spectrum β-lactamases, IQR interquartile range, BMI body mass index, HTN hypertension, DM diabetes mellitus, ICU intensive care unit, PEG percutaneous endoscopic gastrostomy, BLBLIs beta-lactam/beta-lactamase inhibitors, APACHE II score Acute Physiology and Chronic Health Evaluation II score, SOFA score the Sequential Organ Failure Assessment score